← Search another drug
PatientPulse · by PatientPartner
Otezla apremilast
High confidence
~54 public patient pages analyzed, spanning forum threads (Inspire, Psoriasis Association UK, Carenity, Living with PsA), review site aggregates (Drugs.com 487+ reviews, WebMD 208 reviews), and patient-facing blog and brand content.
Executive intelligence
The signal that moves starts & adherence
35%Positive sentiment in discussion
144,030FDA adverse-event reports
23%Flagged serious
66%Reports name female patients
The first-14-days GI dropout window is Otezla's single largest commercial risk: peer-to-peer reassurance that side effects resolve is the highest-ROI intervention available.
- GI side effects (diarrhea, nausea, headache) drive the majority of early discontinuation, yet patients who persist past week two report substantial joint pain relief and skin clearance.
- Insurance access and cost are acute friction points in 2025, with denial, specialty-tier reclassification, and step-therapy requirements forcing patients off a working medication.
- Mood changes and depression are underreported relative to GI effects in patient conversation, yet surface with enough severity to damage relationships and prompt discontinuation.
- The oral, injection-free format is Otezla's strongest emotional differentiator against biologics, especially for patients who have experienced cancer scares or immune-suppression anxiety on prior therapy.